相关实验视频
Updated: Jan 6, 2026

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.3K
一个完全闭环胰岛素和Pramlintide系统的试点门诊评估
Madison Odabassian1, Michael A Tsoukas2,3, Elisa Cohen1
1Department of Biomedical Engineering, McGill University, Montreal, QC, Canada.
Journal of diabetes science and technology
|November 1, 2025
概括
自动化胰岛素和pramlintide系统在消除1型糖尿病管理中的碳水化合物计数方面表现有前途,保持目标血糖水平而不会显著降解. 目前正在进行进一步的研究,以在更大的试验中证实这些发现.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 生物医学工程 生物医学工程
背景情况:
- 1型糖尿病的管理依赖于外源性胰岛素,通常是通过注射或.
- 目前的胰岛素剂量策略需要计算碳水化合物,这通常很困难,容易出现错误.
研究的目的:
- 评估在1型糖尿病管理中消除碳水化合物计数的可行性.
- 评估自动化胰岛素和普拉姆林提德闭环系统在维持血糖控制方面的有效性.
主要方法:
- 一项试点随机对照研究,涉及12名1型糖尿病成年人.
- 参与者被分配到五个干预手臂,包括使用更快的阿斯帕特与碳水化合物计数的对照组.
- 实验组使用自动闭环系统,以更快的aspart或aspart与pramlintide相结合,以不同的比例,不计碳水化合物.
主要成果:
- 与控制组相比,使用更快的阿斯巴特和普拉姆林提德的自动化系统并没有显著降低目标血糖范围 (3.9-10.0 mmol/L) 的时间.
- 目标范围的中位时间在大多数手臂中都是可比的,没有观察到统计学上显著的差异.
- 在阿斯巴特和普拉姆林提德系统中,数字上较高的低血糖 (血糖<3.9 mmol/L) 病例被发现.
结论:
- 自动化胰岛素和普拉姆林提德闭环系统可能为1型糖尿病的碳水化合物计数提供一个可行的替代方案.
- 这些系统有可能在不影响血糖控制的情况下简化糖尿病管理.
- 需要进行更大规模的研究来验证这些初步发现.
更多相关视频
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
644
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
644
Insulin Formulations: Types and Delivery
597
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
597
One-Compartment Open Model for IV Bolus Administration: Estimation of Clearance
318
Clearance is a key pharmacokinetic parameter that quantifies the volume of body fluid from which a drug is entirely removed within a specific time frame. It is crucial in assessing how a drug is eliminated from the body and has critical clinical applications.
In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...
In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...
318
Two-Compartment Open Model: IV Bolus Administration
1.0K
The two-compartment model for intravenous (IV) bolus administration illustrates drug distribution in the body, subdividing it into central and peripheral compartments. This model operates on the concept of two-compartment kinetics. The drug's plasma concentration shows a bi-exponential decline following IV bolus administration, signaling the presence of two disposition processes: distribution and elimination.
The disparity between drug input and the sum of drug transfer rates between...
The disparity between drug input and the sum of drug transfer rates between...
1.0K
One-Compartment Open Model for IV Bolus Administration: General Considerations
649
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
649
Oral Hypoglycemic Agents: Glinides
554
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
554

